Quantum BioPharma announces its response to information about certain stock trading platforms as well as misinformation being circulated on certain social media channels. Certain stock trading platforms mistakenly have the Quantum BioPharma name changed to Unbuzzd Wellness after the news release was issued on May 2. Quantum BioPharma has not changed its name. The company added, “In addition, it has been brought to the attention of Quantum BioPharma that misinformation is being circulated on certain social media channels that Unbuzzd Wellness, the company behind unbuzzd, the scientifically-proven product that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, is doing a reverse takeover transaction into Quantum BioPharma. Currently Unbuzzd Wellness is not doing a RTO transaction with Quantum BioPharma. Unbuzzd Wellness has hired leading audit firm MNP effective May 20, to conduct Public Company Accounting Oversight Board audits of the Company’s financial statements in preparation for a possible initial public offering. MNP, registered with the PCAOB, has the experience and proven track record to deliver audits of the highest standard. Hiring MNP follows the Company’s announcement on February 5, regarding their retention of a New York investment bank to advise on a capital raise and explore an IPO, pending regulatory approval.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Settles Legal Dispute with Former CEO, Receives $2.35 Million
- Quantum BioPharma receives $2.35M from settlement with Raza Bokhari
- Quantum BioPharma’s Licensee Unbuzzd Wellness Prepares for IPO with Audit Firm Engagement
- Quantum BioPharma announces Unbuzzd Wellness hired audit firm
- Quantum BioPharma Gains Approval for Phase 2 Trial of FSD202